Biopharma SHAKTI commits Rs. 10,000 crore to scale biologics manufacturing, translational research, and supply chains over five years, a strategic bet on biosimilars, advanced therapies, and domestic capacity. The fund aims to foster industry-academia incubators, incentives for advanced production, and a stronger export orientation. If executed, the scheme could reduce import dependence, lower therapy costs, and attract global investment into India’s next-generation drug industry. This measure requires clear timelines and state-level coordination.
Trending
- Rooftop Solar Gave Power to Pakistan When Fossil Fuels Failed– it’s Now Called a Boom
- Rehabilitation and outcomes following revision total hip replacement: patients’ experiences, optimised rehabilitation interventions and opioid use (PhD Academy Award)
- Seniors group predicts 3.8% Social Security COLA in 2027
- Why Entrepreneurs Struggle With Dating (And How to Fix It)
- Herbs of Gold and CARiNG Pharmacy inspire women to put their well-being first in a new campaign
- Social Security July 2026 Payment Schedule: When Beneficiaries…
- Four states just made it easier to build wildlife crossings
- 9 eating habits that could be hurting your brain
Monday, July 6
